Noninvasive Prenatal Testing (NIPT) for Fetal Sex Determination: How It Works

NIPT: Screening for Chromosomal Abnormalities and Fetal Sex

Noninvasive Prenatal Testing (NIPT), also called cell-free DNA (cfDNA) screening, analyzes fetal DNA fragments circulating in the pregnant person's blood. These fragments originate from the placenta.

How Fetal Sex Is Determined

  • Standard NIPT (Karyotyping/Whole Genome Sequencing): Sequences all cfDNA. Detects extra/missing chromosomes (trisomies 21, 18, 13). Sex chromosomes (XX or XY) are analyzed simultaneously → reveals fetal sex.
  • Targeted Y-Chromosome Analysis: Some tests specifically detect Y-chromosome sequences. Presence = male (XY); absence = female (XX).

Accuracy

  • Fetal sex accuracy: >99% after 10 weeks gestation.
  • False positives/negatives are rare but possible (e.g., vanishing twin, maternal mosaicism, confined placental mosaicism).

Timing

Can be performed as early as 9–10 weeks gestation. Accuracy for sex determination improves slightly after 10–12 weeks due to higher fetal fraction.

Important Considerations

  • NIPT is a screening test, not diagnostic. Abnormal results require confirmatory diagnostic testing (CVS or amniocentesis).
  • Sex determination is a secondary finding; primary purpose is aneuploidy screening.
  • Results should be interpreted by a qualified clinician/genetic counselor.
  • Ethical considerations: sex selection, disclosure preferences.

Pregnancy & Health - Related Articles